By Fineline Cube 
The Center for Drug Evaluation (CDE) of China has approved LiteDD’s Category 1 product LIT0922 to enter a Phase I clinical study in advanced solid tumors expressing specific markers. This approval marks a significant milestone for LiteDD in developing innovative therapies for oncology patients.
Mechanism of Action
LIT0922 is positioned as the world’s first mTORC2 selective inhibitor capable of penetrating the blood-brain barrier. It accurately targets mTORC2 and synthetic lethal dual targets, while inhibiting the repair of highly lethal DNA double-strand breaks, thereby enhancing its anti-tumor activity. This unique mechanism positions LIT0922 as a potential breakthrough in the treatment of advanced solid tumors.
Preclinical Results
In preclinical studies, LIT0922 demonstrated good anti-cancer activity and safety. The drug’s ability to penetrate the blood-brain barrier and target mTORC2 represents a novel approach to addressing tumors that have historically been challenging to treat, particularly those with central nervous system involvement.-Fineline Info & Tech